publication date: Oct. 30, 2014

NCI CTEP-Approved Trials for the Month of October


The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I

9588: A Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Memorial Sloan Kettering Cancer Center; Sauter, Craig S. (212) 639-3460


9849: A Phase I Study of a Continuous Intravenous Infusion of Recomninant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers. NCI Lymphoid Malignancies Branch; Conlon, Kevin C. (301) 402-2913


9850: A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer. NCI Lymphoid Malignancies Branch; Waldmann, Thomas Alexander. (301) 496-6656


9851: Haploidentical Donor Natural Killer (NK) Cell Infusion with Intravenous Recombinant Human IL-15 (rhIL-15) in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML). University of Minnesota Medical Center-Fairview; Miller, Jeffrey Steven. (612) 624-0123


Phase II

CITN-09: A Phase II Study of MK-3475 in Patients … Continue reading CCL Oct – NCI CTEP Approved Trials

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.